等位基因特异性沉默改善人类肌球蛋白调节轻链突变所致限制型心肌病
本研究在表达人类MYL2致病突变(N47K)的转基因小鼠模型中,探索RNAi疗法对限制型心肌病的治疗潜力。在3日龄和60日龄小鼠注射AAV9包装的shRNA(M7.8L),3日龄单次注射可沉默突变等位基因(RLC-47K)而对正常等位基因(RLC-47N)影响极小,并抑制肥厚生物标志物、减轻心脏重量及左室质量病理性增加,部分恢复心肌细胞收缩、舒张和钙动力学。结果表明靶向RNAi治疗人类限制型心肌病可行、有效且安全。
要点
- AAV9-M7.8L RNAi可等位基因特异性沉默MYL2 N47K突变,对正常等位基因影响小。
- 治疗抑制肥厚生物标志物,减轻心脏重量和左室质量病理性增加。
- 单细胞水平部分恢复收缩、舒张和钙动力学,RNAi通路未饱和。
核心结论
- 靶向人类限制型心肌病致病突变的RNAi治疗在小鼠模型中显示出可行性、疗效和安全性。
研究设计与样本
- 在MYL2 N47K转基因小鼠模型中,于3日龄和60日龄注射AAV9包装的shRNA(M7.8L),治疗后行跑台运动和超声心动图,并取心、肺、肝、肾组织进行病毒嗜性、转录组和蛋白质组分析,分离心肌细胞行单细胞研究。
主要发现
- 3日龄小鼠单次注射AAV9-M7.8L RNAi在注射后16周沉默突变等位基因(RLC-47K),对正常等位基因(RLC-47N)影响极小。
- AAV9-M7.8L RNAi抑制肥厚生物标志物表达,降低心脏重量,减轻左室质量病理性增加。
- 治疗小鼠的单个成年心肌细胞收缩、舒张和钙动力学部分恢复。
- 心脏应激蛋白生物标志物如钙调蛋白依赖性蛋白激酶II和转录激活因子Brg1降低。
- 转录组分析显示AGO1、AGO2和DICER1转录本无显著变化,内源性microRNA保留,提示RNAi通路未饱和。
临床怎么用
- 该策略为限制型心肌病提供了靶向病因治疗的潜在方向,但尚未进入临床,需进一步转化研究。
局限性
- 研究仅在小鼠模型中进行,样本量和统计细节未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Restrictive cardiomyopathy is a rare heart disease associated with mutations in sarcomeric genes and with phenotypic overlap with hypertrophic cardiomyopathy. There is no approved therapy directed at the underlying cause. Here, we explore the potential of an interfering RNA (RNAi) therapeutic for a human sarcomeric mutation in MYL2 causative of restrictive cardiomyopathy in a mouse model. METHODS: A short hairpin RNA (M7.8L) was selected from a pool for specificity and efficacy. Two groups of myosin regulatory light chain N47K transgenic mice were injected with M7.8L packaged in adeno-associated virus 9 at 3 days of age and 60 days of age. Mice were subjected to treadmill exercise and echocardiography after treatment to determine maximal oxygen uptake and left ventricular mass. At the end of treatment, heart, lung, liver, and kidney tissue was harvested to determine viral tropism and for transcriptomic and proteomic analysis. Cardiomyocytes were isolated for single-cell studies. RESULTS: A one-time injection of AAV9-M7.8L RNAi in 3-day-old humanized regulatory light chain mutant transgenic mice silenced the mutated allele (RLC-47K) with minimal effects on the normal allele (RLC-47N) assayed at 16 weeks postinjection. AAV9-M7.8L RNAi suppressed the expression of hypertrophic biomarkers, reduced heart weight, and attenuated a pathological increase in left ventricular mass. Single adult cardiac myocytes from mice treated with AAV9-M7.8L showed partial restoration of contraction, relaxation, and calcium kinetics. In addition, cardiac stress protein biomarkers, such as calmodulin-dependent protein kinase II and the transcription activator Brg1 were reduced, suggesting recovery toward a healthy myocardium. Transcriptome analyses further revealed no significant changes of argonaute (AGO1, AGO2) and endoribonuclease dicer (DICER1) transcripts, and endogenous microRNAs were preserved, suggesting that the RNAi pathway was not saturated. CONCLUSIONS: Our results show the feasibility, efficacy, and safety of RNAi therapeutics directed towards human restrictive cardiomyopathy. This is a promising step toward targeted therapy for a prevalent human disease.
引用
- Zaleta-Rivera K, Dainis A, Ribeiro AJS, et al. Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation. 2019. PMID: 31315475. doi:10.1161/CIRCULATIONAHA.118.036965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。